News stories about Nymox Pharmaceutical Corporation (NASDAQ:NYMX) have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Nymox Pharmaceutical Corporation earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.0712254965384 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Trading summary of Watch List stock – Nymox Pharmaceutical Corporation (NYMX) – Wall Street Morning (wallstreetmorning.com)
- Nymox Application Validated: – GuruFocus.com (gurufocus.com)
- Nymox Pharma (NYMX) Says Its MAA For Fexapotide Triflutate was Validated – StreetInsider.com (streetinsider.com)
- Nymox Announces New Symposium for Company’s BPH Drug at American Urological Association Meeting October 5 (finance.yahoo.com)
Nymox Pharmaceutical Corporation (NYMX) traded down 3.23% during midday trading on Friday, hitting $3.89. The company’s stock had a trading volume of 243,698 shares. The company’s 50-day moving average is $3.66 and its 200 day moving average is $3.86. Nymox Pharmaceutical Corporation has a one year low of $2.67 and a one year high of $5.10. The company’s market cap is $203.71 million.
Separately, ValuEngine downgraded Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a report on Thursday, August 24th.
In other news, Director James George Robinson bought 10,000 shares of Nymox Pharmaceutical Corporation stock in a transaction dated Thursday, August 3rd. The stock was acquired at an average cost of $3.73 per share, with a total value of $37,300.00. Following the acquisition, the director now owns 3,077,550 shares of the company’s stock, valued at $11,479,261.50. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders bought a total of 98,000 shares of company stock valued at $375,725 over the last three months. Company insiders own 54.00% of the company’s stock.
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with our FREE daily email newsletter.